AVIR Insider Trading Activity and SEC Form 4 Filings
AVIR insider trading summary
Over the past 12 months, insiders at Atea Pharmaceuticals, Inc. (AVIR) reported 1 open-market purchase worth $25K by 1 insider and no sales on SEC Form 4. Net insider buying was $25K.
Latest AVIR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 18, 2026 | Polly A. Murphy | Insider | Buy | $25K (6,100 @ $4.17) |
| May 18, 2025 | Polly A. Murphy | Insider | Buy | $25K (6,100 @ $4.17) |
| Jan 16, 2025 | Franklin M Berger | Insider | Buy | $34K (10,000 @ $3.36) |
| Jan 15, 2025 | Franklin M Berger | Insider | Buy | $48K (15,000 @ $3.19) |
| Dec 10, 2024 | Franklin M Berger | Insider | Sell | $1.0M (359,606 @ $2.85) |
| Sep 19, 2024 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | $7K (1,841 @ $4.00) |
| Sep 18, 2024 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | $89K (22,187 @ $4.03) |
| Sep 17, 2024 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | $137K (33,941 @ $4.05) |
| Jun 20, 2024 | Bruce Polsky | Insider | Sell | $61K (17,544 @ $3.49) |
| Jun 5, 2024 | Jean-Pierre Sommadossi | President, CEO, and Chairman | Sell | $4K (1,006 @ $4.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.